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Supplemental Methods: 
 
Luciferase assays and cloning: Constructs containing the wild-type TRAF6 3' UTR or a TRAF6 
3' UTR with one of the two miR-146 binding sites mutated (in pMIR-REPORT) were previously 
described (Taganov et al, 2006). A 600-bp region of the 3' UTR of human EGR3, which contains 
the potential miR-146 binding site, was PCR amplified from HUVEC cDNA using the following 
primers: 5'-TAGAAGGAGAGAGAAGAAGATGAAGTTTGC and 5'-GAATTTCACC 
TTTTCACAATATCAAGCATA (with XbaI linkers), and was cloned into the XbaI site located 
in the 3' UTR of pGL3-promoter (Promega). Similarly a 517-bp region of the 3' UTR of human 
HuR (ELAVL1) was amplified using the following primers: 5'-GAGGCGTAAAATGGCTCTGT 
and 5'-AGTTACAGGCTGGTGGCTTT (with XbaI linkers). The miR-146 seed match in the 
HuR 3' UTR (AGTTCTC) was mutated to (ACAAGAC) by site-directed mutagenesis 
(QuikChange II Kit, Agilent). To generate a luciferase construct that included a concatemer of 
the potential miR-146 binding site in the 3' UTR of EGR3, the following oligos (containing a 5' 
phosphate group) were synthesized: 5'-GGGAGTTTTCCTTTG TTTTAATAAAACTGTT 
CTCAGACATTA, 5'-CCTAATGTCTGAGAACAGTTTTATTAA AACAAAGGAAAACTC; 
miR-146 seed match underlined). These oligos were annealed together, ligated using T4 ligase 
(since they contain CC and GG over-hangs, respectively), and run on an agarose gel. The band 
corresponding to 5 copies of the sequence was gel purified, blunt-end filled using DNA 
polymerase and blunt-end cloned into the XbaI site of pGL3. Oligonucleotides containing a 
mutated miR-146 binding site were also cloned (5'-GGGAGTTTTCCTTTGTTTTAATAAA 
ACTGTAGACAGACATTA and 5'-CCTAATGTCTGTCTACAGTTTTATTAAAACAAAGGA 
AAACTC; mutated miR-146 seed match underlined). The sequence, directionality and the 
number of concatemers inserted were confirmed by DNA sequencing.  
 HeLa cells grown in 12-well dishes were transfected with 1 µg of luciferase construct, 
100 ng of pRL Renilla luciferase construct (Promega) (for normalization of transfection 
efficiency), and 20 nM of control or miR-146a mimic (Dharmacon), using Lipofectamine 2000. 
Cellular lysates were isolated 24 h post-transfection using Passive Lysis Buffer and luciferase 
activity was monitored using the Dual Luciferase Reporter Assay System (Promega) using a 
GloMax 20/20 Luminometer (Promega). 
 A miR-146b promoter/reporter construct (containing a 1 kb fragment of the miR-146b 
proximal promoter) was a kind gift from Dr. E. Flemington (Tulane University Health Sciences 
Center). Site-directed mutagenesis was used to delete a putative EGR binding site 858-848 bp 
upstream of the mature miR-146b sequence using the following primers: 5'-GGGTTCCTG 
GCCCCCTTCCTCCTTTC and 5'-GAAAGGAGGAAGGGGGCCAGGAACCC. HeLa cells 
were transfected with 1 µg of wild-type or EGR-deleted miR-146b promoter/luciferase constructs 
together with a 0.5 µg of an empty or EGR3 expression construct (a kind gift from Dr. J.D. 
Powell (John Hopkins)) as above. A Renilla construct (100 ng) was co-transfected to control for 
transfection efficiency. To analyze NF-κB activity, HUVEC were first transfected with control, 
miR-146a mimic, miR-146 inhibitor, TRAF6 or HuR siRNAs, and after 24 h the cells were 
electroporated with 1 µg of a 5x NF-κB element-luciferase reporter (Promega) and 0.5 µg of 
Renilla (to control for electroporation efficiency) using a Lonza 4D Nucleofector with the P5 
Primary Cell Kit. After 24 h, cells were treated with 10 ng/mL of IL-1β for 6 h, and luciferase 
activity was assessed as above. 
Supporting Information Table I: Primers used for qRT- PCR 
 
Gene Forward Primer (5' -> 3') Reverse Primer (5' -> 3') 
human VCAM1 GTTGAAGGATGCGGGAGTAT GGATGCAAAATAGAGCACGA 
human SELE (E-
Selectin) 
CTGGCCTGCTACCTACCTGT AGCTACCAAGGGAATGTTGG 
human ICAM1 CGGCCAGCTTATACACAAGA GTCTGCTGGGAATTTTCTGG 
human CCL2 (MCP-1) TCATAGCAGCCACCTTCATT CGAGCCTCTGCACTGAGAT 
human EGR1 CAGCACCTTCAACCCTCAG TAACTGGTCTCCACCAGCAC 
human EGR3 ACAATCTGTACCCCGAGGAG GTAAGAGAGTTCCGGGTTGG 
human pri-miR-146a 
(exon 1/intron 1) 
CGGCTGAATTGGAAATGATA TGCTGCCTCTCAAACAGAAG 
human pri-miR-146b AAGAAAGCATGCAAGAGCAG GCCTTGGCATTGATGTTGTA 
human c-FOS TACTACCACTCACCCGCAGA AGTGACCGTGGGAATGAAGT 
human c-JUN GAGAGCGGACCTTATGGCTA GTGAGGAGGTCCGAGTTCTT 
human NOS3 (eNOS) GGCATCACCAGGAAGAAGACC TCACTCGCTTCGCGATCAC 
human TRAF6 CCAAATCCATGCACATTCA TTCTCATGTGTGACTGGGTGT 
human ELAVL1 (HuR) CTCTCGCAGCTGTACCACTC CACGTTGACGCCAGAGAG 
human KLF2 Taqman assay #Hs00360439_g1  
human GAPDH AGGTGAAGGTCGGAGTCAAC GAGGTCAATGAAGGGGTCAT 
human TBP TCG GAG AGT TCT GGG ATT GT CAC GAA GTG CAA TGG TCT TT 
mouse Vcam1 GCACAAAGAAGGCTTTGAAGCA GATTTGAGCAATCGTTTTGTATTCAG 
mouse Sele (E-Selectin) GAACCAAAGACTCGGGCATGT ATGACCACTGCAGGATGCATT 
mouse Icam1 CTGCCTTGGTAGAGGTGACTGA AGGACAGGAGCTGAAAAGTTGTAGA 
mouse Ccl2 (Mcp-1) GTCCCTGTCATGCTTCTGG ATTGGGATCATCTTGCTGGT 
mouse Egr-1 CTACCAATCCCAGCTCATCAAAC CTCATCCGAGCGAGAAAAGC 
mouse Egr-3 AAGCCCTTTGCCTGTGAGTTC CGACTTCTTCTCCTTTTGCTTGA 
mouse Elavl1 (HuR) GTACACCACCAGGCACAGAG CCAAGGTTGTAGATGAAGATGC 
mouse NOS3 (eNOS) CCAAGGTGATGAGCTCTGTG GAAGATATCTCGGGCAGCAG 
mouse Tbp ACCCACCAGCAGTTCAGTAC CTGCTCTAACTTTAGCACCTGT 
 
Supporting Information Figure 1:  TNF-α induces miR-146a and miR-146b expression. 
HUVEC were stimulated with TNF-α and expression of miR-146a and miR-146b was assessed 
by qRT-PCR. Shown is the mean +/- SEM of 2 independent experiments.  NS = non-stimulated.
Supporting Information Figure 2:  Over-expression of miR-146a inhibits monocyte adhesion 
to IL-1β-treated bovine aortic endothelial cells (BAEC). Shown is a representative experiment 
(quantification of 3 images from 3 indendent wells). ANOVA, p<0.0001. ** indicates a significant 
decrease (p<0.01) in the number of cells adhered to IL-1β-treated BAEC transfected with miR-146a 
mimic compared to control mimic.
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Supporting Information Figure 3: miR-146a does not directly regulate EGR-3 - A Luciferase 
construct containing a fragment of the EGR-3 3’ UTR that includes a putative miR-146 binding 
site was transfected into HeLa cells together with control or miR-146a mimic, and luciferase 
activity was measured.  No change in luciferase activity was observed.  As a control, a luciferase 
construct containing the same EGR-3 3’ UTR, but in the inverse orientation, was used.  Data 
from a representative experiment (transfections performed in triplicate) is shown.
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Supporting Information Figure 4: A potential miR-146 binding site in HuR is highly 
conserved across species - A portion of the 3’ UTR of HuR is shown from human, mouse and 
rat, with the potential miR-146 binding site highlighted in yellow. The sequence of miR-146a and 
miR-146b is shown below, with the sequence differences between miR-146a and miR-146b 
indicated in red. The sequence of human, mouse and rat miR-146a and miR-146b are identical 
to that shown.
5’ -- CUUUGAUUUGUAGUUUUAAAGAUUAACCCUCAAAGUUCUCUUCAUAA -- 3’
5’ -- CUUUGAUUUGUAGUUUUAAGGAUUAACCCUCAAAGUUCUCUUCAUAA -- 3’
5’ -- CUUUGAUUUGUAGUUUUAAGGAUUAACCCUCAAAGUUCUCUUCAUAA -- 3’
3’ - UUGGGUACCUUAAGUCAAGAGU - 5’
3’ - UCGGAUACCUUAAGUCAAGAGU - 5’
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Supporting Information Figure 6: HuR knock-down represses THP-1 adhesion to TNF-α-
treated endothelial cells - Shown is a representative experiment (quantification of 3 images in 3 
independent wells). ANOVA, p<0.0001. ** indicates a significant decrease (p<0.01) in THP-1 
adhesion to TNF-α-treated HUVEC transfected with HuR siRNA compared to control siRNA.
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Supporting Information Figure 5: miR-146 controls the expression of HuR mRNA. 
Over-expression of miR-146a in endothelial cells reduced levels of HuR mRNA in IL-1β-treated 
HUVEC (left), as assessed by qRT-PCR, while inhibition of miR-146 increased HuR mRNA (right). 
p-values of significant differences (t-test) are indicated above (n = 4-5).
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Supporting Information Figure 7: Pedicted AU-rich elements (AREs) in the 3’ UTRs of 
genes involved in endothelial activation - Prediction of AREs was performed using AREsite 
(Gruber et al, Nucleic Acids Research, 2010). The coding region of each transcript is indicated in 
orange. The various types of AREs are indicated by colored trianges.
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Supporting Information Figure 8: HuR binds to VCAM-1 and MCP-1 mRNA but does not 
regulate the induction of these genes by IL-1β - (A) HuR was immunoprecipitated from IL-1β-
treated endothelial cells (4 h), RNA was isolated and the expression of several inflammatory genes 
and eNOS (NOS3) was assessed by qRT-PCR. Control immunoprecipitation was performed using 
an antibody to V5. VCAM-1 and MCP-1 were significantly enriched in HuR immunoprecipitates
compared to V5 immunoprecipitates (n = 4). Repeated measures ANOVA, p=0.0021. ** indicates a 
significant difference compared to V5 immunoprecipitation, p<0.01. (B) Expression of VCAM-1 in 
response to IL-1β treatment was not affected by HuR knock-down. A representative blot is shown. 
(C) Expression of MCP-1 was not affected by HuR knock-down, as assessed by ELISA. Shown is the 
mean +/- SEM (n = 3). (D) Activation of NF-κB signaling was not affected by HuR knock-down, but was 
significantly decreased in TRAF6 knock-down cells, as assessed by NF-κB-luciferase reporter 
assay (n = 4). Repeated measures ANOVA, p<0.0001. * indicates a signficant difference, p<0.05.
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Supporting Information Figure 9: The miR-146 targets, HuR and TRAF6, have divergent 
effects on the induction of inflammatory genes - (A) Western blot demonstrating the efficient 
knock-down of HuR or TRAF6. Vinculin was used as a loading control. * indicates a non-
specific band. (B) The induction of SELE, MCP-1 and EGR-3 was assessed in HuR (left) 
or TRAF6 (right) knock-down cells in response to IL-1β treatment. While TRAF6 knock-down 
decreased the induction of these genes, HuR knock-down had no effect (n = 3).
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Supporting Information Figure 10: MicroRNAs previously implicated in regulating 
inflammation are not appreciably altered in miR-146a-/- mice - MicroRNA expression 
was assessed in the hearts of wild-type and miR-146a-/- mice (3-4 months of age) by 
qRT-PCR. Data was normalized to the expression of miR-126 (n = 6).
Supporting Information Figure 11: Expression of eNOS is modestly decreased in 
miR-146a-/- mice - (A) Nos3 (eNOS) mRNA expression was assessed by qRT-PCR in 
wild-type and miR-146a-/- hearts, revealing a trend towards decreased levels in knock-out 
mice (n = 3-6). NS = non-stimulated. (B) Expression of eNOS protein was assessed in 
wild-type and miR-146a-/- hearts by western blot. A representative blot is shown.
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Supporting Information Figure 12: KLF2 mRNA is bound by HuR and knock-down 
of HuR leads to increased levels of KLF2 transcripts - (A) KLF2 mRNA was enriched 
in HuR immunoprecipitates from unstimulated HUVEC compared to control immuno-
precipitates (V5), as assessed by qRT-PCR (t-test, p=0.017, n = 4). (B) KLF2 mRNA 
was increased in HUVEC transfected with HuR siRNA (t-test, p=0.030, n = 5).
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Supporting Information Figure 13: Schematic of a miR-146 feedback loop that  
controls endothelial activation. Pro-inflammatory cytokines activate the NF-!B and  
EGR transcription factors, which induce the expression of leukocyte adhesion molecules  
and chemokines, such as MCP-1. These pathways also induce the expression of  
miR-146, which targets TRAF6 and IRAK1/2, and functions as a negative regulator 
that represses inflammatory signaling. MiR-146 also targets HuR, which represses  
KLF2, a potent transcriptional activator of eNOS. Nitric oxide produced by eNOS is a  
vasodilator and a repressor of leukocyte and platelet adhesion to the endothelium.    
